Date: 2014-08-01
Type of information: Product acquisition
Acquired company: Vancocin®, vancomycin hydrochloride injectable 500 mg, 1 gm and 10 gm and vancomycin hydrochloride oral solution 250 mg and 500 mg- Shire (UK - USA)
Acquiring company: ANI Pharmaceuticals (Israel)
Amount: $11 million
Terms: * On August 1, 2014, ANI Pharmaceuticals announced that it has acquired the US rights for Vancocin® 125 mg and 250 mg capsules from Shire. In addition, ANI acquired from Shire approved ANDAs for the currently non-marketed products vancomycin hydrochloride injectable 500 mg, 1 gm and 10 gm ($45 million in 2013 market value, per IMS Health) and vancomycin hydrochloride oral solution 250 mg and 500 mg. ANI paid $11 million in cash for the rights to Vancocin® together with existing inventories on hand. Following a transition period, ANI intends to launch Vancocin® capsules under its own label during the fourth quarter of 2014. The transaction is immediately accretive and sales of Vancocin® capsules are expected to generate approximately $5.4 million in revenues and $4 million in non-GAAP EBITDA annually.
Details:
Related: Generic drugs
